Articles Tagged With:
-
Transitional coordinator nurses focus on at-risk patients with chronic diseases
Tucson Medical Center keeps its readmission rates low by having transitional coordinators work closely for patients with chronic disease who are at risk for readmissions.
-
Safety net hospital, community providers collaborate to improve transitions
A Care Transitional Task Force at San Francisco General Hospital created a cross-continuum program that has reduced readmissions and increased timely primary care visits for discharged patients.
-
CMS gives the RA program a makeover with more changes in store
CMS has made changes in the scope of work for the Recovery Auditor program and has proposed a number of other changes to be implemented when new RA contracts are issued.
-
Get status right up front for fewer headaches later on
As CMS’ audit program evolves, it’s crucial for hospitals to prevent denials on the front end.
-
Financial stakes rising as auditors set their sights on providers
The Centers for Medicare & Medicaid Services is continuing to tweak its various audit programs, and the changes make it imperative that case managers stay current so they can educate the rest of the staff.
-
ED Push - February 2016 First Issue
-
Azithromycin remains effective in treatment of urogenital chlamydia, study data suggest
Results of a new study, conducted by researchers at the University of Alabama at Birmingham, the Los Angeles-based University of Southern California, and the Los Angeles County Department of Health Services, confirm that azithromycin remains effective in the treatment of urogenital chlamydia.1
-
Snapshot from National HIV Prevention Conference: Strides have been made, yet hurdles remain
The December 2015 National HIV Prevention Conference saw exciting developments announced by the CDC and partners, including new data on trends and disparities in the U.S. HIV epidemic.
-
New option for vaginal discomfort after menopause
Results of a recent Phase III trial suggest that intravaginal dehydroepiandrosterone could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after meno-pause.1 The drug, under development as Intrarosa by Endoceutics, a North American biopharma company, is under review by the FDA.
-
Supreme Court cases loom large in 2016
The most consequential reproductive health-related drama in Congress in 2016 most likely played out in January.